Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Entero Therapeutics (ENTO) just unveiled an announcement.
Timothy R. Ramdeen, a seasoned professional with nearly a decade of experience in private equity, hedge fund investing, and company formation, has been appointed to the Board of a company. He is the founder of Dharma Capital Advisors and has played significant roles in various investment and biotechnology firms, including Sixth Borough Capital Management and Amplexd Therapeutics. Ramdeen, who holds a B.S. in Biology and an MBA in Finance, adds considerable life science industry expertise to the Board. Additionally, the company has seen recent changes to its Audit and Compensation Committees following the resignations of previous members, with new appointments to fill these roles.
Find detailed analytics on ENTO stock on TipRanks’ Stock Analysis page.